Surfactant for Pediatric Acute Lung Injury

Pediatric Clinics of North America

Volumn 55, Issue 3, 2008, Pages 545-575

  Willson, Douglas F ^a   Chess, Patricia R ^b   Notter, Robert H ^b  

^a UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; LUSUPULTIDE; PLACEBO; PORACTANT; SURFACTANT;

ACUTE LUNG INJURY; CLINICAL STUDY; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; MEDICAL RESEARCH; NONHUMAN; PEDIATRICS; RESPIRATORY DISTRESS; REVIEW; SUBSTITUTION THERAPY; THERAPY EFFECT;

HUMANS; INCIDENCE; INFANT, NEWBORN; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SURFACE-ACTIVE AGENTS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 43949140853     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2008.02.016     Document Type: Review

References (222)

1. Bernard G.R., Artigas A., Brigham K.L., et al. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149 (1994) 818-824
2. Murray J.F., Matthay M.A., Luce J.M., et al. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 138 (1988) 720-723
3. American College of Chest Physicians Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies for sepsis. Crit Care Med 20 (1992) 864-874
4. Pollack M.M., Patel K.M., and Ruttimann U.E. PRISM III: an updated pediatric risk of mortality score. Crit Care Med 24 (1996) 743-752
5. Slater A., Shann F., and ANZICS Paediatric Study Group. The suitability of the Pediatric Index of Mortality (PIM), PIM2, the Pediatric Risk of Mortality (PRISM), and PRISM III for monitoring the quality of pediatric intensive care in Australia and New Zealand. Pediatr Crit Care Med 5 (2004) 447-454
6. Shann F., Pearson G., Slater A., et al. Paediatric Index of Mortality (PIM): a mortality prediction model for children in intensive care. Intensive Care Med 23 (1997) 201-207
7. Trachsel D., McCrindle B.W., Nakagawa S., et al. Oxygenation index predicts outcome in children with acute hypoxemic respiratory failure. Am J Respir Crit Care Med 172 (2005) 206-211
8. Hudson L.D., Milberg J.A., Anardi D., et al. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 151 (1995) 293-301
9. Krafft P., Fridrich P., Pernerstorfer T., et al. The acute respiratory distress syndrome; definitions, severity, and clinical outcome. An analysis of 101 clinical investigations. Intensive Care Med 22 (1996) 519-529
10. Doyle R.L., Szaflarski N., Modin G.W., et al. Identification of patients with acute lung injury: predictors of mortality. Am J Respir Crit Care Med 152 (1995) 1818-1824
11. Ware L.B., and Matthay M.A. The acute respiratory distress syndrome. N Engl J Med 342 (2000) 1334-1348
12. Rubenfeld G.D. Epidemiology of acute lung injury. Crit Care Med 31 Suppl (2003) S276-S284
13. Rubenfeld G.D., Caldwell E., Peabody E., et al. Incidence and outcomes of acute lung injury. N Engl J Med 353 (2005) 1685-1693
14. Goss C.H., Brower R.G., Hudson L.D., et al. Incidence of acute lung injury in the United States. Crit Care Med 31 (2003) 1607-1611
15. Pfenninger J., Gerber A., Tschappeler H., et al. Adult respiratory distress syndrome in children. J Pediatr 101 (1982) 352-357
16. Bindl L., Dresbach K., and Lentze M. Incidence of acute respiratory distress syndrome in German children and adolescents: a population based study. Crit Care Med 33 (2005) 209-212
17. Manzano F., Yuste E., Colmenero M., et al. Incidence of acute respiratory distress syndrome and its relation to age. J Crit Care 20 (2005) 274-280
18. Randolph A.G., Wypij D., Venkataraman S.T., et al. Effect of mechanical ventilator weaning protocols on respiratory outcomes in infants and children. A randomized controlled trial. JAMA 288 (2002) 2561-2568
19. Flori H.R., Glidden D.V., Rutherford G.W., et al. Pediatric acute lung injury. Prospective evaluation of risk factors associated with mortality. Am J Respir Crit Care Med 171 (2005) 995-1001
20. The Paediatric Study Group of the Australian and New Zealand Intensive Care Society (ANZICS). Acute lung injury in pediatric intensive care in Australia and New Zealand: a prospective, multicentre, observational study. Pediatr Crit Care Med 8 (2007) 317-323
21. DeBruin W., Notterman D.A., Magid M., et al. Acute hypoxemic respiratory failure in infants and children: clinical and pathologic characteristics. Crit Care Med 20 (1992) 1223-1234
22. Timmons O.D., Havens P.L., and Fackler J.C. Pediatric Critical Care Study Group and the Extracorporeal Life Support Organization. Predicting death in pediatric patients with acute respiratory failure. Chest 108 (1995) 789-797
23. Dahlem P., van Aalderen W.M.C., Hamaker M.E., et al. Incidence and short-term outcome of acute lung injury in mechanically ventilated children. Eur Respir J 22 (2003) 980-983
24. Curley M.A.Q., Hibberd P.L., Fineman L.D., et al. Effect of prone positioning on clinical outcomes in children with acute lung injury. A randomized controlled trial. JAMA 294 (2005) 229-237
25. Willson D.F., Thomas N.J., Markovitz B.P., et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 293 (2005) 470-476
26. Spragg R.G., Lewis J.F., Wurst W., et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 167 (2003) 1562-1566
27. Wang Z., Holm B.A., Matalon S., et al. Surfactant activity and dysfunction in lung injury. In: Notter R.H., Finkelstein J.N., and Holm B.A. (Eds). Lung injury: mechanisms, pathophysiology, and therapy (2005), Taylor Francis Group, Inc, Boca Raton (FL) 297-352
28. Russo T.A., Bartholomew L.A., Davidson B.A., et al. Total extracellular surfactant is increased but abnormal in a rat model of gram-negative bacterial pneumonitis. Am J Physiol 283 (2002) L655-L663
29. Russo T.A., Wang Z., Davidson B.A., et al. Surfactant dysfunction and lung injury due to the E. coli virulence factor hemolysin in a rat pneumonia model. Am J Physiol Lung Cell Mol Physiol 292 (2007) L632-L643
30. Davidson B.A., Knight P.R., Wang Z., et al. Surfactant alterations in acute inflammatory lung injury from aspiration of acid and gastric particulates. Am J Physiol Lung Cell Mol Physiol 288 (2005) L699-L708
31. Wright T.W., Notter R.H., Wang Z., et al. Pulmonary inflammation disrupts surfactant function during P. carinii pneumonia. Infect Immun 69 (2001) 758-764
32. + T-cells. Am J Physiol Lung Cell Mol Physiol 290 (2006) L1087-L1096
33. Petty T., Reiss O., Paul G., et al. Characteristics of pulmonary surfactant in adult respiratory distress syndrome associated with trauma and shock. Am Rev Respir Dis 115 (1977) 531-536
34. Hallman M., Spragg R., Harrell J.H., et al. Evidence of lung surfactant abnormality in respiratory failure. J Clin Invest 70 (1982) 673-683
35. Seeger W., Pison U., Buchhorn R., et al. Surfactant abnormalities and adult respiratory failure. Lung 168 Suppl (1990) 891-902
36. Pison U., Seeger W., Buchhorn R., et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 140 (1989) 1033-1039
37. Gregory T.J., Longmore W.J., Moxley M.A., et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 88 (1991) 1976-1981
38. Günther A., Siebert C., Schmidt R., et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 153 (1996) 176-184
39. Veldhuizen R.A.W., McCaig L.A., Akino T., et al. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome. Am J Respir Crit Care Med 152 (1995) 1867-1871
40. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 13 (1999) 1455-1476
41. Mander A., Langton-Hewer S., Bernhard W., et al. Altered phospholipid composition and aggregate structure of lung surfactant is associated with impaired lung function in young children with respiratory infections. Am J Respir Cell Mol Biol 27 (2002) 714-721
42. Schmidt R., Meier U., Markart P., et al. Altered fatty acid composition of lung surfactant phospholipids in interstitial lung disease. Am J Physiol 283 (2002) L1079-L1085
43. Skelton R., Holland P., Darowski M., et al. Abnormal surfactant composition and activity in severe bronchiolitis. Acta Paediatr 88 (1999) 942-946
44. LeVine A.M., Lotze A., Stanley S., et al. Surfactant content in children with inflammatory lung disease. Crit Care Med 24 (1996) 1062-1067
45. Dargaville P.A., South M., and McDougall P.N. Surfactant abnormalities in infants with severe viral bronchiolitis. Arch Dis Child 75 (1996) 133-136
46. Notter R.H. Lung surfactants: basic science and clinical applications (2000), Marcel Dekker, Inc, New York
47. Notter R.H., and Wang Z. Pulmonary surfactant: physical chemistry, physiology and replacement. Rev Chem Eng 13 (1997) 1-118
48. Holm B.A., Notter R.H., and Finkelstein J.H. Surface property changes from interactions of albumin with natural lung surfactant and extracted lung lipids. Chem Phys Lipids 38 (1985) 287-298
49. Seeger W., Stohr G., Wolf H.R.D., et al. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol 58 (1985) 326-338
50. Holm B.A., and Notter R.H. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J Appl Physiol 63 (1987) 1434-1442
51. Seeger W., Grube C., Günther A., et al. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 6 (1993) 971-977
52. Holm B.A., Enhorning G., and Notter R.H. A biophysical mechanism by which plasma proteins inhibit lung surfactant activity. Chem Phys Lipids 49 (1988) 49-55
53. Fuchimukai T., Fujiwara T., Takahashi A., et al. Artificial pulmonary surfactant inhibited by proteins. J Appl Physiol 62 (1987) 429-437
54. Keough K.W.M., Parsons C.S., and Tweeddale M.G. Interactions between plasma proteins and pulmonary surfactant: pulsating bubble studies. Can J Physiol Pharmacol 67 (1989) 663-668
55. Wang Z., and Notter R.H. Additivity of protein and non-protein inhibitors of lung surfactant activity. Am J Respir Crit Care Med 158 (1998) 28-35
56. Moses D., Holm B.A., Spitale P., et al. Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 164 (1991) 477-481
57. Cockshutt A., and Possmayer F. Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by plasma proteins. Biochim Biophys Acta 1086 (1991) 63-71
58. Seeger W., Lepper H., Hellmut R.D., et al. Alteration of alveolar surfactant function after exposure to oxidant stress and to oxygenated and native arachidonic acid in vitro. Biochim Biophys Acta 835 (1985) 58-67
59. Hall S.B., Lu Z.R., Venkitaraman A.R., et al. Inhibition of pulmonary surfactant by oleic acid: mechanisms and characteristics. J Appl Physiol 72 (1992) 1708-1716
60. Hall S.B., Hyde R.W., and Notter R.H. Changes in subphase surfactant aggregates in rabbits injured by free fatty acid. Am J Respir Crit Care Med 149 (1994) 1099-1106
61. Hickman-Davis J.M., Fang F.C., Nathan C., et al. Lung surfactant and reactive oxygen-nitrogen species: antimicrobial activity and host-pathogen interactions. Am J Physiol 281 (2001) L517-L523
62. Haddad I.Y., Ischiropoulos H., Holm B.A., et al. Mechanisms of peroxynitrite-induced injury to pulmonary surfactants. Am J Physiol 265 (1993) L555-L564
63. Amirkhanian J.D., and Merritt T.A. Inhibitory effects of oxyradicals on surfactant function: utilizing in vitro Fenton reaction. Lung 176 (1998) 63-72
64. Pison U., Tam E.K., Caughey G.H., et al. Proteolytic inactivation of dog lung surfactant-associated proteins by neutrophil elastase. Biochim Biophys Acta 992 (1989) 251-257
65. Holm B.A., Kelcher L., Liu M., et al. Inhibition of pulmonary surfactant by phospholipases. J Appl Physiol 71 (1991) 317-321
66. Enhorning G., Shumel B., Keicher L., et al. Phospholipases introduced into the hypophase affect the surfactant film outlining a bubble. J Appl Physiol 73 (1992) 941-945
67. Lewis J.F., and Jobe A.H. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis 147 (1993) 218-233
68. Seeger W., Günther A., Walmrath H.D., et al. Alveolar surfactant and adult respiratory distress syndrome. Pathogenic role and therapeutic prospects. Clin Invest 71 (1993) 177-190
69. Lachmann B., and van Daal G.-J. Adult respiratory distress syndrome: animal models. In: Robertson B., van Golde L.M.G., and Batenburg J.J. (Eds). Pulmonary surfactant: from molecular biology to clinical practice (1992), Elsevier Science Publishers, Amsterdam 635-663
70. Holm B.A., Wang Z., and Notter R.H. Multiple mechanisms of lung surfactant inhibition. Pediatr Res 46 (1999) 85-93
71. Wang Z., Schwan A.L., Lairson L.L., et al. Surface activity of a synthetic lung surfactant containing a phospholipase-resistant phosphonolipid analog of dipalmitoyl phosphatidylcholine. Am J Physiol 285 (2003) L550-L559
72. Magoon M.W., Wright J.R., Baritussio A., et al. Subfractionation of lung surfactant: implications for metabolism and surface activity. Biochim Biophys Acta 750 (1983) 18-31
73. Wright J.R., Benson B.J., Williams M.C., et al. Protein composition of rabbit alveolar surfactant subfractions. Biochim Biophys Acta 791 (1984) 320-332
74. Gross N.J., and Narine K.R. Surfactant subtypes in mice: characterization and quantitation. J Appl Physiol 66 (1989) 342-349
75. Putz G., Goerke J., and Clements J.A. Surface activity of rabbit pulmonary surfactant subfractions at different concentrations in a captive bubble. J Appl Physiol 77 (1994) 597-605
76. Putman E., Creuwels L.A.J.M., Van Golde L.M.G., et al. Surface properties, morphology and protein composition of pulmonary surfactant subtypes. Biochem J 320 (1996) 599-605
77. Veldhuizen R.A.W., Hearn S.A., Lewis J.F., et al. Surface-area cycling of different surfactant preparations: SP-A and SP-B are essential for large aggregate integrity. Biochem J 300 (1994) 519-524
78. Gross N.J. Extracellular metabolism of pulmonary surfactant: the role of a new serine protease. Annu Rev Physiol 57 (1995) 135-150
79. Lewis J.F., Ikegami M., and Jobe A.H. Altered surfactant function and metabolism in rabbits with acute lung injury. J Appl Physiol 69 (1990) 2303-2310
80. Putman E., Boere A.J., van Bree L., et al. Pulmonary surfactant subtype metabolism is altered after short-term ozone exposure. Toxicol Appl Pharmacol 134 (1995) 132-138
81. Atochina E.N., Beers M.F., Scanlon S.T., et al. P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant. Am J Physiol 278 (2000) L599-L609
82. Kobayashi T., Ganzuka M., Taniguchi J., et al. Lung lavage and surfactant replacement for hydrochloric acid aspiration in rabbits. Acta Anaesthesiol Scand 34 (1990) 216-221
83. Zucker A., Holm B.A., Wood L.D.H., et al. Exogenous surfactant with PEEP reduces pulmonary edema and improves lung function in canine aspiration pneumonitis. J Appl Physiol 73 (1992) 679-686
84. Schlag G., and Strohmaier W. Experimental aspiration trauma: comparison of steroid treatment versus exogenous natural surfactant. Exp Lung Res 19 (1993) 397-405
85. Al-Mateen K.B., Dailey K., Grimes M.M., et al. Improved oxygenation with exogenous surfactant administration in experimental meconium aspiration syndrome. Pediatr Pulmonol 17 (1994) 75-80
86. Sun B., Curstedt T., and Robertson B. Exogenous surfactant improves ventilation efficiency and alveolar expansion in rats with meconium aspiration. Am J Respir Crit Care Med 154 (1996) 764-770
87. Cochrane C.G., Revak S.D., Merritt T.A., et al. Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndrome. Pediatr Res 44 (1998) 705-715
88. Sun B., Curstedt T., Song G.W., et al. Surfactant improves lung function and morphology in newborn rabbits with meconium aspiration. Biol Neonate 63 (1993) 96-104
89. Lachmann B., Hallman M., and Bergman K.-C. Respiratory failure following anti-lung serum: study on mechanisms associated with surfactant system damage. Exp Lung Res 12 (1987) 163-180
90. Nieman G., Gatto L., Paskanik A., et al. Surfactant replacement in the treatment of sepsis-induced adult respiratory distress syndrome in pigs. Crit Care Med 24 (1996) 1025-1033
91. Lutz C., Carney D., Finck C., et al. Aerosolized surfactant improves pulmonary function in endotoxin-induced lung injury. Am J Respir Crit Care Med 158 (1998) 840-845
92. Lutz C.J., Picone A., Gatto L.A., et al. Exogenous surfactant and positive end-expiratory pressure in the treatment of endotoxin-induced lung injury. Crit Care Med 26 (1998) 1379-1389
93. Tashiro K., Li W.-Z., Yamada K., et al. Surfactant replacement reverses respiratory failure induced by intratracheal endotoxin in rats. Crit Care Med 23 (1995) 149-156
94. Eijking E.P., van Daal G.J., Tenbrinck R., et al. Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats. Intensive Care Med 17 (1990) 475-478
95. Sherman M.P., Campbell L.A., Merritt T.A., et al. Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits. J Pediatr 125 (1994) 939-947
96. Berry D., Ikegami M., and Jobe A. Respiratory distress and surfactant inhibition following vagotomy in rabbits. J Appl Physiol 61 (1986) 1741-1748
97. Matalon S., Holm B.A., and Notter R.H. Mitigation of pulmonary hyperoxic injury by administration of exogenous surfactant. J Appl Physiol 62 (1987) 756-761
98. Loewen G.M., Holm B.A., Milanowski L., et al. Alveolar hyperoxic injury in rabbits receiving exogenous surfactant. J Appl Physiol 66 (1989) 1987-1992
99. Engstrom P.C., Holm B.A., and Matalon S. Surfactant replacement attenuates the increase in alveolar permeability in hyperoxia. J Appl Physiol 67 (1989) 688-693
100. Matalon S., Holm B.A., Loewen G.M., et al. Sublethal hyperoxic injury to the alveolar epithelium and the pulmonary surfactant system. Exp Lung Res 14 (1988) 1021-1033
101. Novotny W.E., Hudak B.B., Matalon S., et al. Hyperoxic lung injury reduces exogenous surfactant clearance in vitro. Am J Respir Crit Care Med 151 (1995) 1843-1847
102. Lachmann B., Fujiwara T., Chida S., et al. Surfactant replacement therapy in experimental adult respiratory distress syndrome (ARDS). In: Cosmi E.V., and Scarpelli E.M. (Eds). Pulmonary surfactant system (1983), Elsevier, Amsterdam 221-235
103. Kobayashi T., Kataoka H., Ueda T., et al. Effect of surfactant supplementation and end expiratory pressure in lung-lavaged rabbits. J Appl Physiol 57 (1984) 995-1001
104. Berggren P., Lachmann B., Curstedt T., et al. Gas exchange and lung morphology after surfactant replacement in experimental adult respiratory distress induced by repeated lung lavage. Acta Anaesthesiol Scand 30 (1986) 321-328
105. Lewis J.F., Goffin J., Yue P., et al. Evaluation of exogenous surfactant treatment strategies in an adult model of acute lung injury. J Appl Physiol 80 (1996) 1156-1164
106. Walther F.J., Hernandez-Juviel J., Bruni R., et al. Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant-deficient rats. Am J Respir Crit Care Med 156 (1997) 855-861
107. Walther F., Hernandez-Juviel J., Bruni R., et al. Protein composition of synthetic surfactant affects gas exchange in surfactant-deficient rats. Pediatr Res 43 (1998) 666-673
108. Harris J.D., Jackson F., Moxley M.A., et al. Effect of exogenous surfactant instillation on experimental acute lung injury. J Appl Physiol 66 (1989) 1846-1851
109. Lewis J.F., Ikegami M., and Jobe A.H. Metabolism of exogenously administered surfactant in the acutely injured lungs of adult rabbits. Am Rev Respir Dis 145 (1992) 19-23
110. Lewis J., Ikegami M., Higuchi R., et al. Nebulized vs. instilled exogenous surfactant in an adult lung injury model. J Appl Physiol 71 (1991) 1270-1276
111. van Daal G.J., So K.L., Gommers D., et al. Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. Anesth Analg 72 (1991) 589-595
112. van Daal G.J., Bos J.A.H., Eijking E.P., et al. Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice. Am Rev Respir Dis 145 (1992) 859-863
113. Hall S.B., Venkitaraman A.R., Whitsett J.A., et al. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis 145 (1992) 24-30
114. Hudak M.L., Farrell E.E., Rosenberg A.A., et al. A multicenter randomized masked comparison of natural vs synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr 128 (1996) 396-406
115. Hudak M.L., Martin D.J., Egan E.A., et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics 100 (1997) 39-50
116. Vermont-Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics 97 (1996) 1-6
117. Horbar J.D., Wright L.L., Soll R.F., et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 123 (1993) 757-766
118. Notter R.H., Wang Z., Egan E.A., et al. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids 114 (2002) 21-34
119. Chess P., Finkelstein J.N., Holm B.A., et al. Surfactant replacement therapy in lung injury. In: Notter R.H., Finkelstein J.N., and Holm B.A. (Eds). Lung injury: mechanisms, pathophysiology, and therapy (2005), Taylor Francis Group, Inc, Boca Raton (FL) 617-663
120. Gunther A., Schmidt R., Harodt J., et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J 10 (2002) 797-804
121. Walmrath D., Gunther A., Ghofrani H.A., et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am J Respir Crit Care Med 154 (1996) 57-62
122. Spragg R., Gilliard N., Richman P., et al. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 105 (1994) 195-202
123. Wiswell T.E., Smith R.M., Katz L.B., et al. Bronchopulmonary segmental lavage with Surfaxin (KL(4) - surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med 160 (1999) 1188-1195
124. Willson D.F., Jiao J.H., Bauman L.A., et al. Calf lung surfactant extract in acute hypoxemic respiratory failure in children. Crit Care Med 24 (1996) 1316-1322
125. Willson D.F., Bauman L.A., Zaritsky A., et al. Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Crit Care Med 27 (1999) 188-195
126. Lopez-Herce J., de Lucas N., Carrillo A., et al. Surfactant treatment for acute respiratory distress syndrome. Arch Dis Child 80 (1999) 248-252
127. Hermon M.M., Golej J., Burda H., et al. Surfactant therapy in infants and children: three years experience in a pediatric intensive care unit. Shock 17 (2002) 247-251
128. Herting E., Moller O., Schiffman J.H., et al. Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome. Acta Paediatr 91 (2002) 1174-1178
129. Auten R.L., Notter R.H., Kendig J.W., et al. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 87 (1991) 101-107
130. Lotze A., Knight G.R., Martin G.R., et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J Pediatr 122 (1993) 261-268
131. Lotze A., Mitchell B.R., Bulas D.I., et al. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. J Pediatr 132 (1998) 40-47
132. Khammash H., Perlman M., Wojtulewicz J., et al. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 92 (1993) 135-139
133. Findlay R.D., Taeusch H.W., and Walther F.J. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 97 (1996) 48-52
134. Luchetti M., Casiraghi G., Valsecchi R., et al. Porcine-derived surfactant treatment of severe bronchiolitis. Acta Anaesthesiol Scand 42 (1998) 805-810
135. Luchetti M., Ferrero F., Gallini C., et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr Crit Care Med 3 (2002) 261-268
136. Anzueto A., Baughman R.P., Guntupalli K.K., et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 334 (1996) 1417-1421
137. Gregory T.J., Steinberg K.P., Spragg R., et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 155 (1997) 109-131
138. Clark D.A., Nieman G.F., Thompson J.E., et al. Surfactant displacement by meconium free fatty acids: an alternative explanation for atelectasis in meconium aspiration syndrome. J Pediatr 110 (1987) 765-770
139. Tibby S.M., Hatherill M., Wright S.M., et al. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 162 (2000) 1251-1256
140. Ivascu F.A., and Hirschl R.B. New approaches to managing congenital diaphragmatic hernia. Semin Perinat 28 (2004) 185-198
141. Van Meurs K., and Congenital Diaphragmatic Hernia Study Group. Is surfactant therapy beneficial in the treatment of the term newborn infants with congenital diaphragmatic hernia?. J Pediatr 145 (2004) 312-316
142. Bloom B.T., Kattwinkel J., Hall R.T., et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of RDS. Pediatrics 100 (1997) 31-38
143. Rollins M., Jenkins J., Tubman R., et al. Comparison of clinical responses to natural and synthetic surfactants. J Perinat Med 21 (1993) 341-347
144. Sehgal S.S., Ewing C.K., Richards T., et al. Modified bovine surfactant (Survanta) vs a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. J Natl Med Assoc 86 (1994) 46-52
145. Choukroun M.L., Llanas B., Apere H., et al. Pulmonary mechanics in ventilated preterm infants with respiratory distress syndrome after exogenous surfactant administration: a comparison between two surfactant preparations. Pediatr Pulmonol 18 (1994) 273-298
146. Moller J.C., Schaible T., Roll C., et al. with the Surfactant ARDS Study Group. Treatment with bovine surfactant in severe acute respiratory distress syndrome in children: a randomized multicenter study. Inten Care Med 29 (2003) 437-446
147. Davis J.M., Russ G.A., Metlay L., et al. Short-term distribution kinetics in intratracheally administered exogenous lung surfactant. Pediatr Res 31 (1992) 445-450
148. Espinosa F.F., Shapiro A.H., Fredberg J.J., et al. Spreading of exogenous surfactant in an airway. J Appl Physiol 75 (1993) 2028-2039
149. Grotberg J.B., Halpern D., and Jensen O.E. Interaction of exogenous and endogenous surfactant: spreading-rate effects. J Appl Physiol 78 (1995) 750-756
150. Marks L.B., Notter R.H., Oberdoerster G., et al. Ultrasonic and jet aerosolization of phospholipids and the effects on surface activity. Pediatr Res 17 (1984) 742-747
151. Balaraman V., Meister J., Ku T.L., et al. Lavage administration of dilute surfactants after acute lung injury in neonatal piglets. Am J Respir Crit Care Med 158 (1998) 12-17
152. Balaraman V., Sood S.L., Finn K.C., et al. Physiologic response and lung distribution of lavage vs bolus Exosurf in piglets with acute lung injury. Am J Respir Crit Care Med 153 (1996) 1838-1843
153. Gommers D., Eijking E.P., van't Veen A., et al. Bronchoalveolar lavage with a diluted surfactant suspension prior to surfactant instillation improves the effectiveness of surfactant therapy in experimental acute respiratory distress syndrome (ARDS). Intensive Care Med 24 (1998) 494-500
154. van Der Beek J., Plotz F., van Overbeek F., et al. Distribution of exogenous surfactant in rabbits with severe respiratory failure: the effect of volume. Pediatr Res 34 (1993) 154-158
155. Walmrath D., Grimminger F., Pappert D., et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J 19 (2002) 805-810
156. Marks L.B., Oberdoerster G., and Notter R.H. Generation and characterization of aerosols of dispersed surface active phospholipids by ultrasonic and jet nebulization. J Aerosol Sci 14 (1983) 683-694
157. Wojciak J.F., Notter R.H., and Oberdoerster G. Size stability of phosphatidylcholine-phosphatidylglycerol aerosols and a dynamic film compression state from their interfacial impaction. J Colloid Interface Sci 106 (1985) 547-557
158. Dijk P.H., Heikamp A., and Bambang-Oetomo S. Surfactant nebulization versus instillation during high frequency ventilation in surfactant-deficient rabbits. Pediatr Res 44 (1998) 699-704
159. Ellyett K.M., Broadbent R.S., Fawcett E.R., et al. Surfactant aerosol treatment of respiratory distress syndrome in the spontaneously breathing rabbit. Pediatr Res 39 (1996) 953-957
160. Zelter M., Escudier B.J., Hoeffel J.M., et al. Effects of aerosolized artificial surfactant on repeated oleic acid injury in sheep. Am Rev Respir Dis 141 (1990) 1014-1019
161. Davis J.M., Richter S.E., Kendig J.W., et al. High frequency jet ventilation and surfactant treatment of newborns in severe respiratory failure. Pediatr Pulmonol 13 (1992) 108-112
162. Davis J.M., and Notter R.H. Lung surfactant replacement for neonatal pathology other than primary repiratory distress syndrome. In: Boynton B., Carlo W., and Jobe A. (Eds). New therapies for neonatal respiratory failure: a physiologic approach (1994), Cambridge University Press, Cambridge 81-92
163. Leach C.L., Greenspan J.S., Rubenstein S.D., et al. Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. N Engl J Med 335 (1996) 761-767
164. Leach C.L., Holm B.A., Morin F.C., et al. Partial liquid ventilation in premature lambs with respiratory distress syndrome: efficacy and compatibility with exogenous surfactant. J Pediatr 126 (1995) 412-420
165. Chappell S.E., Wolfson M.R., and Shaffer T.H. A comparison of surfactant delivery with conventional mechanical ventilation and partial liquid ventilation in meconium aspiration injury. Respir Med 95 (2001) 612-617
166. King D.M., Wang Z., Kendig J.W., et al. Concentration-dependent, temperature-dependent non-newtonian viscosity of lung surfactant dispersions. Chem Phys Lipids 112 (2001) 11-19
167. King D.M., Wang Z., Palmer H.J., et al. Bulk shear viscosities of endogenous and exogenous lung surfactants. Am J Physiol 282 (2002) L277-L284
168. Bloom B.T., Delmore P., Rose T., et al. Human and calf lung surfactant: a comparison. Neonatal Intensive Care (1993) 31-35
169. Speer C.P., Gefeller O., Groneck P., et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child 72 (1995) F8-F13
170. Soll R.F., Merritt T.A., and Hallman M. Surfactant in the prevention and treatment of respiratory distress syndrome. In: Boynton B.R., Carlo W.A., and Jobe A.H. (Eds). New therapies for neonatal respiratory failure (1994), Cambridge University Press, New York 49-80
171. Kattwinkel J. Surfactant: evolving issues. Clin Perinatol 25 (1998) 17-32
172. Halliday H.L. Overview of clinical trials comparing natural and synthetic surfactants. Biol Neonate 67 Suppl (1995) 32-47
173. Halliday H.L. Controversies-synthetic or natural surfactant-the case for natural surfactant. J Perinat Med 24 5 (1996) 417-426
174. Soll R.F. Surfactant therapy in the USA: trials and current routines. Biol Neonate 71 (1997) 1-7
175. Mizuno K., Ikegami M., Chen C.-M., et al. Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant. Pediatr Res 37 (1995) 271-276
176. Curstedt T., Jornvall H., Robertson B., et al. Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant: characterization and biophysical activity. Eur J Biochem 168 (1987) 255-262
177. Oosterlaken-Dijksterhuis M.A., Haagsman H.P., van Golde L.M., et al. Characterization of lipid insertion into monomolecular layers mediated by lung surfactant proteins SP-B and SP-C. Biochemistry 30 (1991) 10965-10971
178. Oosterlaken-Dijksterhuis M.A., Haagsman H.P., van Golde L.M., et al. Interaction of lipid vesicles with monomolecular layers containing lung surfactant proteins SP-B or SP-C. Biochemistry 30 (1991) 8276-8281
179. Oosterlaken-Dijksterhuis M.A., van Eijk M., van Golde L.M.G., et al. Lipid mixing is mediated by the hydrophobic surfactant protein SP-B but not by SP-C. Biochim Biophys Acta 1110 (1992) 45-50
180. Revak S.D., Merritt T.A., Degryse E., et al. The use of human low molecular weight (LMW) apoproteins in the reconstitution of surfactant biological activity. J Clin Invest 81 (1988) 826-833
181. Seeger W., Günther A., and Thede C. Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants. Am J Physiol 261 (1992) L286-L291
182. Wang Z., Gurel O., Baatz J.E., et al. Differential activity and lack of synergy of lung surfactant proteins SP-B and SP-C in surface-active interactions with phospholipids. J Lipid Res 37 (1996) 1749-1760
183. Yu S.H., and Possmayer F. Comparative studies on the biophysical activities of the low-molecular-weight hydrophobic proteins purified from bovine pulmonary surfactant. Biochim Biophys Acta 961 (1988) 337-350
184. Wang Z., Baatz J.E., Holm B.A., et al. Content-dependent activity of lung surfactant protein B (SP-B) in mixtures with lipids. Am J Physiol 283 (2002) L897-L906
185. Johansson J., Curstedt T., and Robertson B. Synthetic protein analogues in artificial surfactants. Acta Paediatr 85 (1996) 642-646
186. Johansson J., Gustafsson M., Zaltash S., et al. Synthetic surfactant protein analogs. Biol Neonate 74 Suppl (1998) 9-14
187. Walther F.J., Gordon L.M., Zasadzinski J.M., et al. Surfactant protein B and C analogues. Mol Genet Metab 71 (2000) 342-351
188. Robertson B., Johansson J., and Curstedt T. Synthetic surfactants to treat neonatal lung disease. Mol Med Today 6 (2000) 119-124
189. Cochrane C.G., Revak S.D., Merritt T.A., et al. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med 153 (1996) 404-410
190. Cochrane C.G., and Revak S.D. Surfactant lavage treatment in a model of respiratory distress syndrome. Chest 116 Suppl (1999) 85S-86S
191. Cochrane C.G., and Revak S.D. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 254 (1991) 566-568
192. Cochrane C.G., and Revak S.D. Protein-phospholipid interactions in pulmonary surfactant. Chest 105 (1994) 57S-62S
193. Merritt T.A., Kheiter A., and Cochrane C.G. Positive end-expiratory pressure during KL4 surfactant instillation enhances intrapulmonary distribution in a simian model of respiratory distress syndrome. Pediatr Res 38 (1995) 211-217
194. Revak S., Merritt T., Cochrane C., et al. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res 39 (1996) 715-724
195. Revak S.D., Merritt T.A., Hallman M., et al. The use of synthetic peptides in the formation of biophysically and biologically active surfactants. Pediatr Res 29 (1991) 460-465
196. Ikegami M., and Jobe A.H. Surfactant protein-C in ventilated premature lamb lung. Pediatr Res 44 (1998) 860-864
197. Davis A.J., Jobe A.H., Hafner D., et al. Lung function in premature lambs and rabbits treated with a recombinant SP-C surfactant. Am J Respir Crit Care Med 157 (1998) 553-559
198. Lewis J., McCaig L., Hafner D., et al. Dosing and delivery of a recombinant surfactant in lung-injured sheep. Am J Respir Crit Care Med 159 (1999) 741-747
199. Hafner D., Germann P.-G., and Hauschke D. Effects of rSP-C surfactant on oxygenation and histology in a rat-lung-lavage model of acute lung injury. Am J Respir Crit Care Med 158 (1998) 270-278
200. Spragg R.G., Smith R.M., Harris K., et al. Effect of recombinant SP-C surfactant in a porcine lavage model of acute lung injury. J Appl Physiol 88 (1999) 674-681
201. Spragg R.G., Lewis J.F., Rathgeb F., et al. Intratracheal instillation of rSP-C surfactant improves oxygenation in patients with ARDS. [abstract]. Am J Respir Crit Care Med 165 (2002) A22
202. Notter R.H., Schwan A.L., Wang Z., et al. Novel phospholipase-resistant lipid/peptide synthetic lung surfactants. Mini Rev Med Chem 7 (2007) 932-934
203. Waring A.J., Walther F.J., Gordon L.M., et al. The role of charged amphipathic helices in the structure and function of surfactant protein B (SP-B). J Pept Res 66 (2005) 364-374
204. Walther F.J., Waring A.J., Sherman M.A., et al. Hydrophobic surfactant proteins and their analogues. Neonatology 91 (2007) 303-310
205. Turcotte J.G., Lin W.H., Pivarnik P.E., et al. Chemical synthesis and surface activity of lung surfactant phospholipid analogs. II. Racemic N-substituted diether phosphonolipids. Biochim Biophys Acta 1084 (1991) 1-12
206. Turcotte J.G., Sacco A.M., Steim J.M., et al. Chemical synthesis and surface properties of an analog of the pulmonary surfactant dipalmitoyl phosphatidylcholine analog. Biochim Biophys Acta 488 (1977) 235-248
207. Chang Y., Wang Z., Notter R.H., et al. Synthesis and interfacial behavior of sulfur-containing analogs of lung surfactant dipalmitoyl phosphatidylcholine. Bioorg Med Chem Lett 14 (2004) 5983-5986
208. Chang Y., Wang Z., Schwan A.L., et al. Surface properties of sulfur- and ether-linked phosphonolipids with and without purified hydrophobic lung surfactant proteins. Chem Phys Lipids 137 (2005) 77-93
209. Notter R.H., Wang Z., Wang Z., et al. Synthesis and surface activity of diether-linked phosphoglycerols: potential applications for exogenous lung surfactants. Bioorg Med Chem Lett 17 (2007) 113-117
210. Davy J.A., Wang Z., Notter R.H., et al. Synthesis of sulfur-containing glycerophospholipids. J Sulfur Chem 28 (2007) 45-72
211. Wang Z., Chang Y., Schwan A.L., et al. Activity and inhibition resistance of a phospholipase-resistant synthetic exogenous surfactant in excised rat lungs. Am J Respir Cell Mol Biol 37 (2007) 387-394
212. 2 activities are increased in human adult respiratory distress syndrome. Am J Physiol 269 (1995) L109-L118
213. 2 in ARDS pathogenesis. Molec Med Today 5 (1999) 244-249
214. 2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. J Lab Clin Med 104 (1984) 873-881
215. Kostopanagiotou G., Routs C., Smyrniotis V., et al. Alterations in bronchoalveolar lavage fluid during ischemia-induced acute hepatic failure in the pig. Hepatology 37 (2003) 1130-1138
216. Attalah H.L., Wu Y., Alaoui-El-Azher M., et al. Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury. Eur Respir J 21 (2003) 1040-1045
217. 2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med 33 (2003) 772-779
218. 2 and eosinophil lysophospholipases causes surfactant dysfunction: a mechanism for small airway closure in asthma. Chest 123 (2003) 255S
219. Walther F.J., Waring A.J., Hernandez-Juviel J.M., et al. Dynamic surface activity of a fully-synthetic phospholipase-resistant lipid/peptide lung surfactant. PLoS ONE 2 10 (2007) e1039
220. Kendig J.W., Notter R.H., Cox C., et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks gestation. N Engl J Med 324 (1991) 865-871
221. Notter R.H., Apostolakos M., Holm B.A., et al. Surfactant therapy and its potential use with other agents in term infants, children and adults with acute lung injury. Perspectives in Neonatology 1 4 (2000) 4-20
222. Pryhuber G.S., D'Angio C.T., Finkelstein J.N., et al. Combined-modality therapies for lung injury. In: Notter R.H., Finkelstein J.N., and Holm B.A. (Eds). Lung injury: mechanisms, pathophysiology, and therapy (2005), Taylor Francis Group, Inc, Boca Raton (FL) 779-838